Ilke Wicke

Ilka has studied Organic Chemistry and obtained her PhD from the Johann Wolfgang Goethe University in Frankfurt. Following her graduation she spent a year in academic research as a postdoctoral fellow at the Sloan Kettering Cancer Center in New York investigating retroviral gene therapy approaches. She joined Boehringer Ingelheim in 1996 as head of an interdisciplinary research laboratory specializing in new drug discovery approaches. Thereafter, Ilka spent more than 13 years in the Corporate Licensing Division of Boehringer Ingelheim where she was responsible for the evaluation, negotiation and the management of several global licensing transactions. In 2009, Ilka participated in the creation of the Boehringer Ingelheim Venture Fund as a strategic component of Boehringer Ingelheim and has since then been an active Investment Manager in the Fund. Over the last years, Ilka has been involved in several investments of the fund. She served as board member of Promethera Bioscience in Brussels, AgoMab in Ghent and Pcovery in Copenhagen, Metabomed in Tel Aviv, Cardior Pharmaceuticals in Hannover and Anagenesis in Strasbourg. In addition, she was member of the Investment Committee of the High Tech Gründer Fund (HTGF III), the largest publicly backed Seed Investment Fund in Germany based in Bonn.